Ketamine is a fully synthetic drug, first created in a laboratory in 1962. It was derived from phencyclidine (PCP), a powerful dissociative anesthetic that proved too dangerous for routine medical use. A chemist named Calvin Stevens, working for the pharmaceutical company Parke-Davis, modified the PCP molecule to produce a shorter-acting, safer alternative. That modified compound became ketamine.
How Ketamine Was Derived From PCP
In the late 1950s, PCP was being explored as a surgical anesthetic, but patients experienced severe hallucinations, agitation, and prolonged delirium during recovery. Parke-Davis wanted a compound that could deliver PCP’s powerful pain-blocking and dissociative effects without the extreme side effects. Calvin Stevens began systematically altering PCP’s chemical structure to find that compound.
The key modification involved swapping parts of the PCP molecule. PCP’s chemical name is 1-(1-phenylcyclohexyl)-piperidine. Ketamine’s full name is 2-(2-chlorophenyl)-2-(methylamino)cyclohexanone. In practical terms, Stevens added a chlorine atom to the ring structure, replaced the piperidine group with a smaller methylamino group, and introduced a ketone (a specific type of oxygen bond) to the cyclohexane ring. These changes preserved the dissociative anesthetic properties while making the drug act faster, wear off sooner, and produce less severe psychological disturbance. The compound was originally labeled CI-581 during its early development and testing before receiving the name ketamine.
The Chemical Building Blocks
Today, ketamine is manufactured through multi-step chemical synthesis in a lab. It does not come from a plant, animal, or mineral source. The process starts with petroleum-derived chemical precursors and builds the molecule through a series of controlled reactions.
One common starting material is 2-chlorobenzonitrile, a compound made from chlorine and benzene derivatives. This is reacted with cyclopentylmagnesium bromide in what chemists call a Grignard reaction, producing a substance called 2-chlorophenyl cyclopentyl ketone. That intermediate then goes through bromination (adding bromine atoms), amination (adding a nitrogen-containing group), and a molecular rearrangement where the five-membered ring expands into a six-membered ring, forming the core structure of ketamine.
Another widely used route starts with 2-(2-chlorophenyl)cyclohexanone. This compound is chemically oxidized, then reduced using zinc powder and an acid (formic or acetic) to produce norketamine, a close relative missing one small chemical group. Norketamine is then converted into ketamine by adding a methyl group through a reaction with formaldehyde. This final step, called reductive methylation, completes the molecule.
Both routes ultimately require the same core ingredients: chlorinated aromatic compounds, cyclohexane-based structures, nitrogen sources, and various reagents to stitch them together. The entire process takes place under controlled laboratory conditions.
A Surprising Natural Occurrence
Although ketamine was invented in a lab, researchers have since discovered it in one natural source. A soil-dwelling fungus called Pochonia chlamydosporia produces ketamine as a metabolite. Scientists at Brazil’s Federal University of Minas Gerais identified ketamine in extracts from this fungus and confirmed it was the same molecule by chemical analysis. The fungal ketamine showed the ability to paralyze and kill nematode worms (tiny parasitic roundworms), suggesting the fungus may produce it as a natural defense mechanism.
This discovery is notable but has no connection to how ketamine is manufactured for medical or recreational use. All ketamine used by humans is synthetically produced. The fungal finding simply demonstrates that the molecular structure can arise through biological processes as well as chemical ones.
Racemic Ketamine vs. Esketamine
When ketamine is synthesized through standard methods, it produces a 50/50 mixture of two mirror-image versions of the molecule, called the S-form and R-form. These are like left and right hands: identical in composition but oriented differently in three-dimensional space. This mixture is called racemic ketamine, and it’s what has been used in anesthesia for decades.
The S-form (esketamine) binds more potently to receptors in the brain and has become the basis for newer treatments, including a nasal spray approved for treatment-resistant depression. Isolating pure esketamine from the racemic mixture requires an extra separation step. One efficient method uses tartaric acid, a naturally occurring compound found in grapes, to selectively crystallize the S-form out of solution. The leftover R-form can then be chemically scrambled back into a 50/50 mixture and run through separation again, allowing manufacturers to convert up to 67% of the starting material into the desired S-form rather than wasting half of it.
From Battlefield Anesthetic to Modern Medicine
Ketamine’s synthetic origins at Parke-Davis in 1962 led to rapid clinical development. It was tested in human volunteers and found to produce effective anesthesia with a wide margin of safety, meaning the dose needed to anesthetize someone was far below the dose that could cause fatal complications. This made it especially valuable in field conditions where careful monitoring was difficult. It saw extensive use during the Vietnam War as a battlefield anesthetic.
Over the following decades, its applications expanded well beyond surgery. Clinicians recognized its value for pain management, and researchers in the early 2000s discovered its rapid antidepressant effects, which work through an entirely different brain mechanism than traditional antidepressants. All of these uses trace back to the same synthetic molecule Calvin Stevens built by modifying PCP’s structure more than 60 years ago.